Not for use in US.

Calculates the Bone Scan Index (BSI) from selected hotspots

Based on our unique Artificial Neural Network (ANN), our product provides you with a unique feature which automatically classifies and quantifies the hotspots, calculates and presents the Bone Scan Index value (BSI).

BSI is a reproducible and quantitative imaging biomarker reflecting the tumor burden in bone as a percentage of the total skeletal mass calculated from bone scintigraphy. BSI is a prognosis and treatment response indicator in prostate cancer patients with skeletal metastases.



What can EXINI bone do for you?

Display of Images

Includes our unique standardization and normalization of whole body bone scans.
Average count levels of the normal skeleton are calculated so the skeleton is always displayed with the same grey scale level, i.e. the images are not scaled to the maximum pixel value, which usually represents the bladder.

Find out more »

Classification of hotspots

EXINI boneBSI presents potential metastases detected using a complex mathematical method, instead of a simple threshold method.

This classification of hotspots is based on artificial neural networks that have been trained using a large database of bone scans interpreted by top experts in the field. Artificial neural networks classify hotspots as either high or low probability of metastasis.

Find out more »

Bone Scan Index / quantification

The Quantification Module includes calculation of the Bone Scan Index (BSI) and the number of metastases.

Automatically calculates the BSI values, an imaging biomarker that reflects the extent of skeletal involvement by tumor in whole body bone scans.

Find out more »

Summary page

The summary page presents a complete report, based on the classification of hotpots and the quantification of BSI. The summary page can easily be exported to an information system or PDF file with text and images by the physician.

Find out more »

Bone Scan Index

Quantification of bone scan
in advanced prostate cancer

As an imaging biomarker, Bone Scan Index (BSI), can support physicians to determine treatment response, and to prognosticate development in patients with advanced prostate cancer and bone metastases. For this patient group, the BSI can add value to Prostate Specific Antigen (PSA). . Until the EXINI bone™ product was launched, there was no automated process providing accurate BSI calculations. Thanks to EXINI BSI, BSI is developing into a widespread tool for nuclear medicine physicians, urologists and oncologists.

Automated BSI scoring can also play an important role in clinical trials of new drugs aimed at this patient group.

With the help of EXINI BSI software, BSI can be brought into daily clinical work were it will assist physicians in their effort to efficiently treat prostate cancer.

Follow the latest news about BSI »

Explore EXINI bone


Advanced algorithms and…

The EXINI products are based on four cornerstones: expert knowledge of nuclear medicine, image processing, artificial neural networks, and large image databases. Find out more about our technology.